YD Bio (YDES)
Builds cancer-testing and ophthalmology programs alongside clinical-trial drug supply.
$3.74
Pre-market−0.16 (−4.10%)
At close$3.90(+3.31%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions8 holders · as of Mar 31, 2026 | 0.23% | 159.5K shares | |
| Insiders4 holders · as of Jul 1, 2026 | 76.86% | 54.44M shares | |
| Otherremainder | 22.91% | 16.23M shares |
70.83M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Institutions13F, as of Mar 31, 2026
8 holders · 159.5K shares · 0 new positions · 5 increased · 1 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 60.2K | 0.09% | +1.9K | May 15, 2026 |
| Cerity Partners LLC | 32.4K | 0.05% | 0 | May 15, 2026 |
| Cypress Capital Management LLC (WY) | 30.7K | 0.04% | +3.2K | May 8, 2026 |
| Citadel Advisors LLC | 19.5K | 0.03% | +7.9K | May 15, 2026 |
| UBS Group AG | 11.6K | 0.02% | +4.4K | May 5, 2026 |
| Wolverine Asset Management LLC | 4.9K | 0.01% | +2.4K | May 4, 2026 |
| Morgan Stanley | 223 | 0.00% | −76 | May 15, 2026 |
| FMR LLC | 1 | 0.00% | 0 | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.